ARTICLE | Clinical News
Fosrenol lanthanum carbonate: Phase IV data
May 1, 2006 7:00 AM UTC
Data from an open-label, active-controlled, Phase IV study in 2,520 ESRD patients with hyperphosphatemia showed that 12 weeks of Fosrenol treatment provided mean serum phosphorus control while signifi...